Genetic variations linked to weight loss, side effects from GLP-1 drugs
By Nancy Lapid April 10 (Reuters) – Weight-loss responses to GLP-1 obesity drugs, and risks of side effects, may be linked to genetic variants, according to a study conducted by DNA-testing service 23AndMe. The study of nearly 28,000 23AndMe users who reported taking the weight-loss drugs found that a mutation in GLP1R, the gene for…